Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM.

Neurology. 2009 Jun 9;72(23):1989-93. doi: 10.1212/WNL.0b013e3181a92b96.

2.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
3.

Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.

Sanford M, Lyseng-Williamson KA.

Drugs. 2011 Oct 1;71(14):1865-91. doi: 10.2165/11207540-000000000-00000. Review.

PMID:
21942977
4.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
5.

Early treatment and dose optimisation BENEFIT and BEYOND.

Hartung HP.

J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50. Review.

PMID:
16170501
6.

Statin treatment in multiple sclerosis: a systematic review and meta-analysis.

Pihl-Jensen G, Tsakiri A, Frederiksen JL.

CNS Drugs. 2015 Apr;29(4):277-91. doi: 10.1007/s40263-015-0239-x. Review.

PMID:
25795002
7.

Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].

Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A.

Portland (OR): Oregon Health & Science University; 2010 Aug.

8.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
9.

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

Carter NJ, Keating GM.

Drugs. 2010 Aug 20;70(12):1545-77. doi: 10.2165/11204560-000000000-00000. Review.

PMID:
20687620
10.

Fingolimod for relapsing-remitting multiple sclerosis.

La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G.

Cochrane Database Syst Rev. 2016 Apr 19;4:CD009371. doi: 10.1002/14651858.CD009371.pub2. Review.

PMID:
27091121
11.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
12.

Alemtuzumab for multiple sclerosis.

Riera R, Porfírio GJ, Torloni MR.

Cochrane Database Syst Rev. 2016 Apr 15;4:CD011203. doi: 10.1002/14651858.CD011203.pub2. Review.

PMID:
27082500
13.

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui MK, Kinter E.

PLoS One. 2015 Jun 3;10(6):e0127960. doi: 10.1371/journal.pone.0127960. eCollection 2015. Review.

14.

Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.

Zivadinov R, Munschauer FE, Ramanathan M, Benedict RH, Weinstock-Guttman B.

Drugs Today (Barc). 2008 Aug;44(8):601-13. doi: 10.1358/dot.2008.44.8.1242250. Review.

PMID:
18846271
15.

Interferon beta for multiple sclerosis.

Connelly JF.

Ann Pharmacother. 1994 May;28(5):610-6. Review.

PMID:
8069001
16.

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

Tremlett HL, Oger J.

Neurology. 2003 Aug 26;61(4):551-4. Review.

PMID:
12939437
17.

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.

Freedman MS.

Expert Opin Biol Ther. 2014 Aug;14(8):1207-14. doi: 10.1517/14712598.2014.924496. Epub 2014 Jun 26. Review.

18.

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis.

Cocco E, Marrosu MG.

Ther Clin Risk Manag. 2015 May 8;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015. Review.

19.

[Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?].

Vermersch P.

Presse Med. 2004 Feb 14;33(3):180-6; discussion 192. Review. French.

PMID:
15029033
20.

New and emerging treatment options for multiple sclerosis.

Polman CH, Uitdehaag BM.

Lancet Neurol. 2003 Sep;2(9):563-6. Review.

PMID:
12941579

Supplemental Content

Support Center